Tvardi Therapeutics, Inc. (TVRD)
| Market Cap | 243.81M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 9.36M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,367 |
| Open | 25.26 |
| Previous Close | 25.61 |
| Day's Range | 25.16 - 27.00 |
| 52-Week Range | 8.14 - 31.32 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 39.00 (+49.66%) |
| Earnings Date | May 27, 2025 |
About TVRD
Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis. Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency. Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Su... [Read more]
Analyst Forecast
According to one analyst, the rating for TVRD stock is "Strong Buy" and the 12-month stock price forecast is $39.0.
News
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases.